ArticleNature communications2024
Strengthening and expanding capacities in clinical trials: advancing pandemic prevention, preparedness and response in Africa.
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Establishing a filarial clinical research platform in a resource-limited setting: Lessons and experiences from Tanzania.PLoS neglected tropical diseases · 2026Trial
- Inspiring, shaping and sustaining an African research & development agenda.Nature medicine · 2026Article
- Review
- Research capacity and decolonisation in Sub-Saharan Africa: a bibliometric analysis.BMJ global health · 2026Article
- A python's embrace? Insurance and the global clinical trial.Health research policy and systems · 2026Article
- Three decades of clinical trials in Portuguese-speaking Africa: a comprehensive scoping review protocol.BMJ open · 2026Article
- The precarious state of community engagement in African clinical trials: A systematic review of funding, workforce gaps, and the path to institutionalization.PLOS global public health · 2026Article
- Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.Human vaccines & immunotherapeutics · 2025Review
- Frontier sites in clinical trials: Opportunities, challenges, and models.Contemporary clinical trials communications · 2025Article
- Patterns of Oncological Clinical Trials in African Countries: A Scoping Review.Journal of cancer prevention · 2025Review
- Article
- Inequalities in access to industry-funded interventional phase I-IV drug trials in epilepsy.Epilepsia open · 2025Article
- Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Health Research Ethics in Southern Africa: Building Capacity and Cultivating Excellence.Journal of empirical research on human research ethics : JERHRE · 2025Article
- Bridging the vaccine divide.Nature medicine · 2025Article
- Resurgence of malaria and artemisinin resistance in Africa requires a concerted response.Nature medicine · 2025Article
- Data science without borders: bridging the divide in data science capacity across African health institutions.Frontiers in public health · 2025Article
- Combating antimicrobial resistance in Africa: a strategic roadmap for surveillance, stewardship, and research.Frontiers in cellular and infection microbiology · 2025Review
- Publishing in theJournal of public health in Africa · 2024Article
- Equitable Data Sharing in Collaborative Health Research in Sub-Saharan Africa: A Translational Bioethics Perspective.Ethics & human researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Nicaise NdembiAfrica Centres for Disease Control and Prevention (Africa CDC), Haile Garment Square, Addis Ababa, Ethiopia. Nicaisen@africacdc.org.ORCID 0000-0001-5131-3136
Tadesse T MekonenAvacare Health, Grand bay, Mauritius, South Africa.
Morenike Oluwatoyin FolayanDepartment of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria.
Nebiyu DerejeAfrica Centres for Disease Control and Prevention (Africa CDC), Haile Garment Square, Addis Ababa, Ethiopia.
Adriaan KrugerNuvoteq, Hazelwood Incubator, 47 Hazelwood Rd, Hazelwood, Pretoria, South Africa.
Joseph FokamChantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.ORCID 0000-0002-1501-2763
Elvis TemfackAfrica Centres for Disease Control and Prevention (Africa CDC), Haile Garment Square, Addis Ababa, Ethiopia.
Tajudeen RajiAfrica Centres for Disease Control and Prevention (Africa CDC), Haile Garment Square, Addis Ababa, Ethiopia.
Jean NachegaStellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa.ORCID 0000-0002-2862-4443
Yap BoumInstitut Pasteur de, Bangui, Central African Republic.
Trevor A CrowellHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.ORCID 0000-0001-5947-265X
Alain Ngashi NgongoAfrica Centres for Disease Control and Prevention (Africa CDC), Haile Garment Square, Addis Ababa, Ethiopia.
Souleymane MboupInstitut de Recherche en Santé, de Surveillance Épidémiologique et de Formations (IRESSEF), Diamniadio, Senegal.
Francine NtoumiFondation Congolaise pour la Recherche Médicale, Republic of Congo and Institute of Tropical Medicine, University of Tübingen, Tuebingen, Germany.
Glaudina LootsDepartment of Science and Technology, Pretoria, South Africa.
Michael MakangaGlobal Health EDCTP3 Joint Undertaking, Brussels, Belgium.
Samba SowCenter for Vaccine Development (CVD) at the Mali Ministry of Health and Social Development, Bamako, MD, Mali.
Salim Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban and Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0002-4986-2133
John NkengasongBureau of Global Health Security and Diplomacy, President's Emergency Plan for AIDS Relief, Washington, DC, USA.
Funding
Impact of Non - B HIV - 1 Subtype on second line Protease Inhibitor Regimens in Africa (INSPIRE)R01AI147331 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E, NDEMBI, NICAISE · 2020 to 2025
$2.9MNIAID NIH HHS R01 AI147331U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) US NIH R01 AI147331-04
Abstract
PubMed holds no abstract for this paper.
Indexed as
Clinical Trials as TopicCOVID-19PandemicsAfricaCapacity BuildingHumansSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.